

This is a promotional symposium organised by Merck for UK healthcare professionals only. Scroll down to access the BAVENCIO® Prescribing Information and adverse event reporting.



# Optimising the treatment experience for patients with urothelial carcinoma (UC)

Friday 14<sup>th</sup> June 2024  
08:00–08:45

Merck Sponsored  
Satellite Symposium

## UK ONCOLOGY FORUM 2024

Doubletree by Hilton,  
Brighton



Join us at the Merck-sponsored symposium where our expert faculty, Dr Giuseppe Banna and Dr Mark Prentice, will discuss the UK's current treatment landscape, the latest real-world evidence in diagnosis, treatment and survival, and how to optimise the treatment pathway for UC patients.

## FACULTY



**Dr Giuseppe Banna**  
Consultant Medical Oncologist,  
Portsmouth Hospitals University  
NHS Trust and Honorary  
Associate Professor,  
University of Portsmouth



**Dr Mark Prentice**  
Consultant Clinical Oncologist,  
Royal Free Hospital NHS  
Foundation Trust

## AGENDA

08:00–08:05	<b>Welcome and introductions</b> <b>Dr Giuseppe Banna</b>
08:05–08:20	<b>Improving treatment standards in advanced UC: What can we learn from clinical practice?</b> <b>Dr Giuseppe Banna</b>
08:20–08:35	<b>Real-world experiences with UC: Challenging patient cases</b> <b>Dr Mark Prentice</b>
08.35–08:45	<b>Q&amp;A &amp; panel discussion</b> <b>All faculty</b>
08:45	<b>Meeting close</b> <b>Dr Giuseppe Banna</b>

BAVENCIO® (avelumab) is indicated as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy.

Prescribing Information for BAVENCIO® can be accessed [here](#).

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk>  
Adverse events should also be reported to Merck Serono Limited  
Tel: +44(0)20 8818 7373 or email: [medinfo.uk@merckgroup.com](mailto:medinfo.uk@merckgroup.com)